Table 4.

Prevalence of fibroid symptoms before, after treatment, 3, 6, and 9 month after treatment according to groups (Data are presented as n (%*)).

Fibroid symptoms	2.5 mg	5 mg	P**
Pelvic pain
Before treatment	81 (73.6)	87 (79.1)	.171
3-month treatment	14 (13.7)	9 (8.5)	.114
3-month followup	21 (21.4)	24 (23.1)	.389
6-month followup	31 (33.3)	24 (23.3)	.060
9-month followup	33 (36.7)	25 (25.0)	.041
Pelvic pressure
Before treatment	74 (67.9)	73 (65.8)	.369
3-month treatment	3 (2.9)	3 (2.8)	.481
3-month followup	8 (8.2)	8 (7.7)	.451
6-month followup	18 (19.5)	8 (7.8)	.008
9-month followup	19 (21.1)	10 (10.0)	.018
Urinary symptoms
Before treatment	45 (41.3%)	35 (31.5)	.066
3 month treatment	3 (2.9)	3 (2.8)	.481
3-month followup	7 (7.1)	8 (7.7)	.454
6-month followup	12 (12.9)	7 (6.8)	.074
9-month followup	12 (13.3)	6 (6.0)	.042
Lumbar pain
Before treatment	59 (54.1)	56 (50.5)	.292
3-month treatment	3 (2.9)	1 (1.9)	.147
3-month followup	4 (4.1)	9 (8.7)	.093
6-month followup	15 (16.1)	10 (9.7)	.089
9-month followup	17 (18.9)	11 (11.0)	.062
Rectal pain
Before treatment	29 (26.6)	37 (33.3)	.138
3-month treatment	4 (3.9)	2 (1.9)	.190
3-month followup	2 (2.0)	3 (2.9)	.350
6-month followup	6 (6.5)	6 (5.8)	.427
9-month followup	5 (5.6)	5 (5.0)	.432
Dyspareunia
Before treatment	58 (53.2)	62 (55.9)	.347
3-month treatment	1 (1.0)	2 (1.9)	.300
3-month followup	5 (5.1)	8 (7.7)	.227
6-month followup	9 (9.7)	8 (7.8)	.318
9-month followup	12 (13.3)	6 (6.0)	.042
Hypermenorrhea
Before treatment	79 (71.8)	73 (66.4)	.191
3-month treatment	4 (3.9)	2 (1.9)	.190
3-month followup	23 (23.5)	15 (15.4)	.073
6-month followup	38 (40.9)	21 (20.4)	<0.001
9-month followup	37 (41.1)	24 (24.0)	.005
Metrorrhagia
Before treatment	15 (13.8)	22 (19.8)	.115
3-month treatment	0	0	—
3-month followup	2 (2.0)	0	.072
6-month followup	3 (3.2)	2 (1.9)	.285
9-month followup	2 (2.2)	1 (1.0)	.250

*Percentages on the number of subjects in each evaluative period (Figure 1).

**Normal approximation for proportions.